A$ 4.58
Key Takeaways
Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of NAN.AX is 4.7 and suggests 3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
